

IV

CONTENTS

"What Kind of Games Are Being Played?", editorial from California Pharmacist, page 9, November 1973.....	Page 10167
"Some Manufacturers Disclose Sources of Supply," article from California Pharmacist, pages 7-9, October 1973.....	10168
"Manufacturer Disclosures—Part II," article from California Pharmacist, pages 14-15, November 1973.....	10171
Letter dated February 25, 1974, to Senator Gaylord Nelson, chairman, Subcommittee on Monopoly, from Dr. Edward G. Feldmann, associate executive director for scientific affairs, American Pharmaceutical Association.....	10184
Letter dated February 22, 1974, to Dr. Edward G. Feldmann, associate executive director for scientific affairs, American Pharmaceutical Association, from Senator Gaylord Nelson, chairman, Subcommittee on Monopoly.....	10205
Letter dated February 25, 1974, to Senator Gaylord Nelson, chairman, Subcommittee on Monopoly, from Dr. Edward G. Feldmann, associate executive director for scientific affairs, American Pharmaceutical Association.....	10206
Letter dated February 27, 1974, to Senator Gaylord Nelson, chairman, Subcommittee on Monopoly, from Dr. Edward G. Feldmann, associate executive director for scientific affairs, American Pharmaceutical Association.....	10211
Statements appearing in Pharmaceutical Manufacturers Association publications in connection with their claim regarding responsibility for 95 percent of the U.S. drug supply.....	10224
Membership list of the National Association of Pharmaceutical Manufacturers as of January 1974.....	10248
Letter dated February 26, 1974, to Senator Gaylord Nelson, chairman, Subcommittee on Monopoly, from Joseph Barrows, chairman of the board, National Association of Pharmaceutical Manufacturers.....	10255
Veterans Administration experimental contract FSC Schedule 65, part I, section C, Drugs and Pharmaceutical Products, issued December 18, 1973, for the period January 1 through December 31, 1974.....	10459

APPENDIX

Exhibits provided by the U.S. General Accounting Office:	
Prepared statement of Hon. Elmer B. Staats, Comptroller General of the United States.....	10497
"Problems In Obtaining And Enforcing Compliance With Good Manufacturing Practices For Drugs," a report submitted to the U.S. Congress by the Comptroller General of the United States, B-164031(2), March 29, 1973.....	10520
"How to Improve the Procurement and Supply of Drugs in the Federal Government," a report submitted to the U.S. Congress by the Comptroller General of the United States, B-164031(2), December 6, 1973.....	10577
Exhibits provided by the Food and Drug Administration:	
Prepared statement of Hon. Alexander M. Schmidt, M.D., Commissioner, Food and Drug Administration.....	10638
Drug compliance information letter, dated February 28, 1973, from the Office of Compliance, Bureau of Drugs, Food and Drug Administration, to manufacturers, repackers, and relabelers of drug products.....	10657
Drug compliance information letter, dated May 7, 1973, from the Office of Compliance, Bureau of Drugs, Food and Drug Administration, to manufacturers, repackers, and relabelers of drug products.....	10660
Drug compliance information letter, dated July 18, 1973, from the Office of Compliance, Bureau of Drugs, Food and Drug Administration, to manufacturers, repackers, and relabelers of drug products.....	10663
Drug compliance information letter, dated October 5, 1973, from the Office of Compliance, Bureau of Drugs, Food and Drug Administration, to manufacturers, repackers, and relabelers of drug products.....	10666
Drug compliance information letter, dated January 23, 1974, from the Office of Compliance, Bureau of Drugs, Food and Drug Administration, to manufacturers, repackers, and relabelers of drug products.....	10669
Food and Drug Administration new regulations pertaining to the marketing of digoxin products which became effective on January 22, 1974.....	10673